Bariatric surgery and surgical devices in obesity management


  • Chinnadorai Rajeswaran Mid-Yorkshire NHS Hospital Trust, UK
  • Vinod Joseph Mid-Yorkshire NHS Hospital Trust, UK
  • Manish Kushe Mid-Yorkshire NHS Hospital Trust, UK
  • Zaidi Zulfiqar Mid-Yorkshire NHS Hospital Trust, UK
  • David McLaren Mid-Yorkshire NHS Hospital Trust, UK
  • Rhodri King Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, UK
  • Robert Ryder Sandwell and West Birmingham Hospitals, UK



obesity, bariatric surgery, devices


Obesity levels worldwide are reaching epidemic proportions with resultant strain on healthcare systems and individual wellbeing. To date, bariatric surgery is the management option that produces the greatest degree of weight loss which can be maintained in the long term along with a reduction in obesity-associated comorbidities such as diabetes and fewer cardiovascular events. Roux-en-Y gastric bypass, laparascopic gastric band and sleeve gastrectomy are the most widely performed bariatric procedures but, despite low perioperative mortality and complication rates, these procedures may not be suitable for all patients due to other factors. Newer surgical techniques are being developed both laparoscopically and endoscopically, in addition to the use of less invasive non-surgical devices that can achieve weight loss, by (1) increasing satiety such as gastric pacing and vagal nerve inhibition and (2) reducing absorption through aspiration of gastric contents, duodenal sheaths and thermal ablation of the duodenal mucosa. This article reviews current and future bariatric surgical procedures and introduces non-surgical devices that may increasingly feature in the management of obesity.


Finkelstein EA, Trogdon JG, Cohen JW, et al. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood) 2009;28:w822.

World Health Organization. Factsheet number 311. Obesity and overweight. (accessed July 2015).

Patel SR. Reduced sleep as an obesity risk factor. Obes Rev 2009;10(Suppl 2):61-8.

Taheri S, Lin L, Austin D, et al. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. PLoS Med 2004;1:e62.

Spiegel K, Tasali E, Penev P, et al. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med 2004; 141:846-50.

St-Onge MP, O'Keeffe M, Roberts AL, et al. Short sleep duration, glucose dysregulation and hormonal regulation of appetite in men and women. Sleep 2012;35:1503-10.

Public Health England Obesity. (accessed July 2015).

Health and Social Care Information Centre. The Health Survey for England 2006. London.

Butland B, Jebb S, Kopelman P, et al. Tackling obesities: future choices – project report (2nd Ed). London: Foresight Programme of the Government Office for Science, 2007.

National Audit Office. Tackling obesity in England. London: The Stationery Office, 2001 (accessed July 2015).

Adams TD, Stroup AM, Gress RE, et al. Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver Spring) 2009;17:796-802.

Brancatisano A, Wahlroos S, Matthews S, et al. Gastric banding for the treatment of type 2 diabetes mellitus in morbidly obese. Surg Obes Relat Dis 2008;4:423-9.

Busetto L, Mirabelli D, Petroni ML, et al. Comparative long-term mortality after laparoscopic adjustable gastric banding versus nonsurgical controls. Surg Obes Relat Dis 2007;3:496-502.

Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007;357:741-52.

Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007;357:753-61.

Solomon CG, Dluhy RG. Bariatric surgery: quick fix or long-term solution? N Engl J Med 2004;351:2751-3.

Korenkov M, Sauerland S, Junginger T. Disclosures surgery for obesity. Curr Opin Gastroenterol 2005;21:679-83.

Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg 2013;23:427-36.

Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg 2014;149:275-87.

Sjostrom L. Review of the key results from the Swedish Obese Subjects (SOS) trial: a prospective controlled intervention study of bariatric surgery. J Intern Med 2013;273:219-34.

Lim RB, Blackburn GL, Jones DB. Benchmarking best practices in weight loss surgery. Curr Probl Surg 2010;47:79-174.

Tritos NA, Mun E, Bertkau A, et al. Serum ghrelin levels in response to glucose load in obese subjects post-gastric bypass surgery. Obes Res 2003;11:919-24.

Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346:1623-30.

Korner J, Bessler M, Cirilo LJ, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 2005;90:359-65.

Karamanakos SN, Vagenas K, Kalfarentzos F, et al. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg 2008;247:401-07.

le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006;243:108-14.

Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 2004;240:236-42.

Roth CL, Reinehr T, Schernthaner GH, et al. Ghrelin and obestatin levels in severely obese women before and after weight loss after Roux-en-Y gastric bypass surgery. Obes Surg 2009;19:29-35.

Greiner T, Bäckhed F. Effects of the gut microbiota on obesity and glucose homeostasis. Trends Endocrinol Metab 2011;22:117-23.

Meek CL, Lewis HB, Reimann F, Gribble FM, Park AJ. The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. Peptides 2016;77:28-37.

López-Nava G, Bautista-Castaño I, Jimenez A, et al. The Primary Obesity Surgery Endolumenal (POSE) procedure: one-year patient weight loss and safety outcomes. Surg Obes Relat Dis 2015;11:861-5.

Kim SB, Kim KK, Chung JW, et al. Initial experiences of laparoscopic gastric greater curvature plication in Korea: a review of 64 cases. J Laparoendosc Adv Surg Tech A 2015;25:793-9.

Tang Y, Tang S, Hu S. Comparative efficacy and safety of laparoscopic greater curvature plication and laparoscopic sleeve gastrectomy: a meta-analysis. Obes Surg 2015;25:2169-75.

Skrekas G, Antiochos K, Stafyla VK. Laparoscopic gastric greater curvature plication: results and complications in a series of 135 patients. Obes Surg 2011;21:1657-63.

Rasera I Jr, Coelho TH, Ravelli MN, et al. A comparative, prospective and randomized evaluation of Roux-en-Y gastric bypass with and without the silastic ring: a 2-year follow up preliminary report on weight loss and quality of life. Obes Surg 2016;26:762-8.

Mahawar KK, Jennings N, Brown J, Gupta A, Balupuri S, Small PK. "Mini" gastric bypass: systematic review of a controversial procedure. Obes Surg 2013;23:1890-8.

Lee WJ, Ser KH, Lee YC, Tsou JJ, Chen SC, Chen JC. Laparoscopic Roux-en-Y vs. mini-gastric bypass for the treatment of morbid obesity: a 10-year experience. Obes Surg 2012;22:1827-34.

Parmar CD, Mahawar KK, Boyle M, et al. Mini Gastric Bypass: first report of 125 consecutive cases from United Kingdom. Clin Obes 2016;6:61-7.

Sanchez-Pernaute A, Herrera MA, Perez-Aguirre ME, et al. Single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S). One to three-year follow-up. Obes Surg 2010;20:1720-6.

Ikramuddin S, Blackstone RP, Brancatisano A, et al. Effect of reversible intermittent intra-abdominal vagal nerve blockade on morbid obesity: the ReCharge randomized clinical trial. JAMA 2014;312:915-22.

Miller K, Hoeller E, Aigner F. The implantable gastric stimulator for obesity: an update of the European experience in the LOSS (Laparoscopic Obesity Stimulation Survey) study. Treat Endocrinol 2006;5:53.

Cha R, Marescaux J, Diana M. Updates on gastric electrical stimulation to treat obesity: Systematic review and future perspectives. World J Gastrointest Endosc 2014;6:419-31.

Sullivan S, Stein R, Jonnalagadda S, et al. Aspiration therapy leads to weight loss in obese subjects: a pilot study. Gastroenterology 2013;145:1245-52.

Forssell H, Norén E. A novel endoscopic weight loss therapy using gastric aspiration: results after 6 months. Endoscopy 2015;47:68-71.

de Jonge C, Rensen SS, Verdam FJ, et al. Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes. Obes Surg 2013;23:1354-60.

Majumder S, Birk J. A review of the current status of endoluminal therapy as a primary approach to obesity management. Surg Endosc 2013;27:2305-11.

Escalona A, Pimentel F, Sharp A, et al. Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal-jejunal bypass liner. Ann Surg 2012;255:1080-5.

Betzel B, Koehestanie P, Aarts EO, et al. Safety experience with the duodenal-jejunal bypass liner: an endoscopic treatment for diabetes and obesity. Gastrointest Endosc 2015;82:845-52.

GI Dynamics. Data as of 30 June 2015.

Zheng Y, Wang M, He S, Ji G. Short-term effects of intragastric balloon in association with conservative therapy on weight loss: a meta-analysis. J Transl Med 2015;13:246.

Fuller NR, Pearson S, Lau NS, et al. An intragastric balloon in the treatment of obese individuals with metabolic syndrome: a randomized controlled study. Obesity 2013;21:1561-70. (accessed January 2016).







Most read articles by the same author(s)